Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

Journal of Bone and Mineral Research - United States
doi 10.1002/jbmr.3848

Related search